Asthma and Obstructive Sleep Apnea

Yi-Xian Qiao¹, Yi Xiao²

¹Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
²Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

Abstract

Objective: To get a comprehensive understanding about the relationship between obstructive sleep apnea (OSA) and asthma by reviewing the epidemiology, pathophysiology, and clinical manifestation and then summarizing the latest progress on diagnosis and treatment.

Data Sources: Articles referred in this review were mainly collected from a comprehensive search of the PubMed published in English from 1990 to 2015 with the terms “OSA” and “asthma” as the main keywords. Highly regarded older publications were also included.

Study Selection: Information about the features of the two diseases in common, the pathophysiologic association between them and their current treatments from the literature search were identified, retrieved, and summarized.

Results: Both OSA and asthma are very prevalent conditions. The incidences of them have kept on rising in recent years. Asthma is often accompanied by snoring and apnea, and OSA often combines with asthma, as well. They have many predisposing and aggravating factors in common. Possible shared direct mechanistic links between them include mechanical effects, intermittent hypoxia, nerve reflex, inflammation, leptin, etc. Indirect mechanistic links include medication, nose diseases, smoking, obesity, and gastroesophageal reflux disease. Since OSA presents many similar features with nocturnal asthma, some scholars termed them as a sole syndrome – “alternative overlap syndrome,” and proved that asthma symptoms in those patients could be improved through the treatment of continuous positive airway pressure.

Conclusions: OSA and asthma are closely associated in pathogenesis, symptoms, and therapies. With the growing awareness of the relationship between them, we should raise our vigilance on the coexistence of OSA in those difficult-to-control asthmatic patients. Further studies are still needed to guide the clinical works.

Key words: Asthma; Continuous Positive Airway Pressure; Gastroesophageal Reflux Disease; Obesity; Obstructive Sleep Apnea

Introduction

Both obstructive sleep apnea (OSA) and asthma are prevalent diseases, and the incidences of them have shown a gradual increase recently. OSA usually involves the upper airways (nasal, oral, and pharyngeal passages), manifested with inspiratory flow limitation and repeated airway collapse during sleep, in combination with many daytime symptoms such as sleepiness, morning headaches, depression, concentration difficulties, and memory loss. Asthma is usually characterized by chronic inflammation, airway hyperresponsiveness (AHR), and reversible expiratory flow limitation. Recently, massive researches have been done on the interaction between the two diseases, but still reached no consensus. This review has presented multiple acknowledged connections on epidemiology, pathophysiology, clinical manifestation, and the latest progress on diagnosis and therapies. Theoretically, OSA and asthma are closely associated in those respects.

Epidemiology

OSA has been recognized as a major public health problem. It is a disease prevalent in middle-aged males and is estimated to affect 2–4% of the adult population.[1] Asthma is one of the most common chronic respiratory system diseases, and...
as of 2004, it was estimated that as many as 300 million people of all ages suffer from it.\[2\]

Previously, numerous studies have demonstrated the high prevalence of OSA in asthmatics. In a prospective cohort of Australian Busselton Health Study, asthma emerged as one of the independent risk factors for the development of habitual snoring (relative risk, odds ratio (OR) = 2.8).\[2\] A questionnaire survey done by Ekici et al. showed that asthma was associated with a higher likelihood of snoring and apneas versus those in controls (54.0% vs. 16.7% and 41.4% vs. 7.0%, respectively), and these symptoms mentioned above could cause further impairment in health-related quality of life.\[4\] Auckley et al. also reported that asthmatics posed a high risk of self-reported snoring and daytime sleepiness when compared with the general internal medicine population (18.5% vs. 8.0% and 46.1% vs. 34.3%, respectively) independent of the severity of asthma (P = 0.183).\[5\] However, Julien et al. came to a different conclusion on this issue through the polysomnography (PSG) device that OSA seemed to be more prevalent among patients with severe asthma versus those moderate and controlled ones, thus revealed the potential pathophysiologic interaction between OSA and asthma severity.\[6\] Despite the prevalence of OSA in asthma, patients with OSA were also reported with many asthma symptoms. Alharbi et al. investigated 606 patients with OSA and demonstrated a high prevalence of asthma (35.1%).\[7\] OSA was proved to be significantly associated with asthma exacerbation. Ten Brinke et al. regarded OSA as one of the key determinants of recurrent asthma attacks (OR = 3.4).\[8\]

**Pathophysiology**

Recently, there have been numerous reports in the literature, suggesting an association on pathophysiology between OSA and asthma. Though the definite relationship has not been established, several theories have been proposed. Based on the pathways, it could be classified as direct or indirect effects.

**Direct Effects**

**Mechanical effects**

Mechanical effects between OSA and asthma are bidirectional. Previously, Ballard et al. found that the functional residual capacity of the asthmatics fell during sleep, which might partly contribute to the nocturnal increase in airflow resistance.\[9\] This could attenuate the caudal traction on upper airways and induce airway collapse.\[10\] On the other side, patients with OSA often present habitual snoring. The intermittent vibration caused by turbulent air leads to local inflammation and edema around the uvula, soft palate, and upper airway, which increase the airflow resistance and then trigger or aggravate asthma. Previous studies held the idea that the airway collapse in OSA during sleep was mainly due to the increasing inspiratory resistance. However, there has been a growing experimental support for the viewpoint that the airway obstruction is both an inspiratory and expiratory events.\[11\] Bijaoui et al. calculated the resistance over both inspiration and expiration and found an increase in the expiratory lung resistance during obstructed breathing in stage two and slow wave sleep, compared with wakefulness and arousal values.\[12\] The above-mentioned increasing expiratory resistance was supposed to exacerbate the combined asthma. Besides, the high negative intrathoracic pressure caused by airway closure acts on the airway mucosa increases its sensitivity and results in more asthma attacks.

**Intermittent hypoxia**

In OSA, the episodes of partial or complete obstruction of the upper airway during sleep lead to the intermittent hypoxia. Repetitive hypoxia and reoxygenation increase the reactive oxygen species, followed by complex oxidative stress cascade downstream and inflammation, which can involve the airway and aggravate asthma. Another plausible explanation is the insulin resistance (IR), which is not only significantly associated with progression of sleep disordered intermittent hypoxia\[13\] but also acts as a main bridge to metabolic syndrome. The metabolic syndrome carries a condition of systemic inflammation that could potentially explain the influence on asthma onset and severity.\[14\] On the contrary, the weakened pulmonary function caused by asthma to some extent aggravates the hypoxia of OSA as well.

**Nerve reflex**

Recently, growing data have suggested a possible causal neurogenic association between OSA and asthma. One explanation for our finding is the repeated stimulations on neural receptors in the oropharyngeal region of OSA causing potent neural reflex bronchoconstriction.\[15\] In addition to the mechanical trauma, the increase in vagal tone that occurs during apneic episodes in OSA stimulates muscarinic receptors in the central airway and results in bronchoconstriction and nocturnal asthma symptoms. Some animal studies even found that mild hypoxia can enhance the bronchial responsiveness to methacholine and histamine.\[16\] In addition, the hypoxia or hypercapnia in OSA excites peripheral chemical receptor in carotid body and increases the airway sensitivity. OSA also influences the respiratory center’s regulation on sleep-related bronchomotor tone and decreases the stability of airway. Therefore, the treatment of continuous positive airway pressure (CPAP) could eliminate the chronic stimulation on oropharynx and stabilize the upper airway to decrease vagal tension.

**Inflammation**

Asthma is a chronic systemic inflammatory disorder, manifested by inflammatory cells infiltration which affects the strength of respiratory muscles. Correspondingly, the presence of both systemic and airway inflammations has also been suggested in OSA patients.\[17\] Its local airway inflammation mainly results from the mechanical trauma of airway closure and snoring-induced vibration, as well as the local oxidative stress. Aihara et al. pointed out that there was an obviously increasing level of interleukin-6 (IL-6), IL-8, tumor necrosis factor-α (TNF-α), and vascular endothelial growth factor (VEGF) in respiratory secretions of OSA patients, and all the above-mentioned biomarkers
The increasing aldosterone leads to liquid condensate and nitrotyrosine and 8-isoprostane levels in asthmatics, which induces significant production of proinflammatory markers such as CRP, IL-6, and TNF-α. Possible mechanisms that may account for the airway neutrophilia in OSA are intermittent hypoxia and upper airway trauma. Karamanl et al. provided a 3-month CPAP treatment to 35 moderate-to-severe asthmatics and found that all markers such as CRP, IL-6, and TNF-α in exhaled breath condensate and nitrotyrosine and 8-isoprostane levels in serum were decreased significantly. Therefore, they came to the conclusion that CPAP treatment could significantly decrease the local inflammation of OSA and also, to some extent, help decrease systemic oxidative stress levels in serum. While improvements have been demonstrated in many studies, its certain effect on local and systemic inflammation is still debatable. 

Leptin

Leptin, which is mainly synthesized and secreted by adipose tissue, has been known to be elevated in OSA patients. It usually results from factors such as obesity and intermittent hypoxia. As the airway epithelial cells express receptors for adipokins leptin and adiponectin, the increasing leptin was proved to be closely correlated with AHR. An animal model research done by Shore et al. proved that the administration of leptin to mice could increase both AHR and serum IgE levels. Besides, leptin also has proinflammatory effect as a member of the IL-6 family of cytokines. Possible reason is considered as the alveolar macrophages’ unique sensitivity to leptin in overweight and obese asthmatics, which induces significant production of proinflammatory cytokines.

Vascular endothelial growth factor

Some scholars also pointed out the importance of VEGF in the pathogenesis of the two diseases. VEGF is a hypoxia-sensitive glycoprotein, and its expression can be promoted by OSA and asthma. As a glycoprotein that stimulates the endothelial cell proliferation and neoangiogenesis, VEGF may contribute to bronchial inflammation, hyperresponsiveness, and vascular remodeling in those patients. A recent study completed by Simcock et al. supported a critical role for VEGF in vascular remodeling in asthma.

Cardiac dysfunction

OSA can provoke or worsen cardiac dysfunction. Usually, in nonrapid eye movement sleep period, the whole cardiovascular system presents a relaxed state. Metabolic rate and sympathetic nerve activity decrease significantly while the vagal activity rises. Since sleep structure is destroyed in OSA, the cardiovascular system loses its normal relaxed condition. Intermittent hypoxia and hypercapnia easily induce endothelial dysfunction, which finally results in cardiac ischemia, cardiac remodeling and thereby aggravates the process of heart failure. In the meanwhile, the enhanced sympathetic activity and negative intrathoracic pressure lead to the intermittent increasing after load of left ventricular, causing or worsening heart failure. Those above-mentioned changes not only decrease lung compliance and increase peripheral airway resistance, but also activate the renin-angiotensin-aldosterone system. The increasing aldosterone leads to liquid accumulation around the neck, increasing airflow resistance, and worsening OSA. Other studies also suggested that heart failure could induce bronchoconstriction and AHR due to the airway’s hyperresponsiveness to cholinergic stimuli. Airway resistance was demonstrated to be higher due to mucosa and pulmonary edema, and the bronchial walls were thicken in those patients who are susceptible to asthma.

Others

There are still several other connecting pathways implicated in the relationship of the two diseases. Tamisier et al. pointed out that inspiratory and expiratory resistances during the night in OSA are much higher than those in the daytime. The upper airway resistance increases at the end of the expiratory phase before the inspiratory-induced airway collapse. Given those findings and recognition, the asthma characteristic increasing expiratory airflow resistance may potentially contribute to the upper airway collapsibility during inspiration. Another reasonable mechanism is that poor sleep quality caused by severe asthma can lower arousal thresholds, leading to frequent nocturnal arousals and increasing upper airway collapsibility.

Indirect Effects

Glucocorticoids

Glucocorticoids usually constitute first choice treatment in asthma control, and recently it has been proposed as a contributing factor of OSA. Yigla et al. selected 22
difficult-to-treat asthmatics who had received long-term or frequent bursts of oral corticosteroids. It finally came out that 21 (95%) of them were diagnosed with OSA. The proportion was much larger than that of the patients receiving intermittent use of corticosteroids, which identified a dose-response relationship between corticosteroid use and OSA. Though the mechanism by which the two conditions are linked is not fully illuminated, possible reasons proposed recently are as follows: Inhaled corticosteroids cause fat deposition in and around the upper airway, narrowing the airway cross-section area; glucocorticoids can induce myopathy of the airway dilator muscles, which influences the airway dilation; glucocorticoids worsen obesity.

**Nasal diseases**

Nasal cavity acts as the main breathing route during sleep. Nasal inflammation causes mucosa hyperemia, edema, nasal stenosis, and obstruction. Increased nasal resistance results in higher negative oropharyngeal pressure during inspiration and predisposes to airway collapse. A study done by Kalpaklioglu et al. demonstrated that patients with allergic rhinitis or nonallergic rhinitis have higher apnea-hypopnea index and nasal resistance. In addition, the trauma on the upper airway produced by snoring and cycles of airway closure/reopening in OSA can also trigger or worsen local inflammation of the nasal and pharyngeal mucosa.

A majority of the asthmatics have nasal diseases as rhinitis and nasal polyposis. In this condition, bacterial colonization from infected areas falls into the lower airway, and proinflammatory and bronchoconstrictive cytokines transfers to the systemic circulation, thus provoking and aggravating local or systemic inflammation and airway obstruction. The chronic inflammatory stimulation on the mucosa can lead to reflective bronchospasm through the way innervated by parasympathetic nose-bronchial reflection. Besides, the substitution of the mouth for the obstructive nose to breath resulting in excessive dry air going into the lower airways, easily causing asthma attack.

**Smoking**

Smoking is a common risk factor in progression of the two conditions. It can worsen asthma and OSA symptoms. The proximal airway inflammation provoked by smoking has been postulated as the likely mechanism, which increases the surface mucus secretion and induces airway edema, thereby increasing the airway resistance and worsening airway obstruction. Another described mechanism is the hazardous ingredients in cigarettes, which can directly irritate the airways, damage mucosa within a short time, and trigger the symptoms of wheezing, cough, and sputum production. Besides, it was documented that smoking increased the production of leukotrienes, one of the most important inflammatory mediators in asthma attack.

**Obesity**

Obesity is a known major risk factor for OSA. A research showed that males with neck perimeter larger than 40 cm or females larger than 36 cm were at higher risk of OSA compared with those controls. It has been shown that the neck perimeter is more closely correlated to the severity of the syndrome. Reasons focus on the following aspects: Fat deposits in the neck region, narrowing the pharyngeal airway, weakening the pharyngeal muscles' support, and then making the airway easily to collapse. Fat that deposits in the abdomen can also increase the intra-abdominal pressure, which influence the diaphragmatic motion and decreases the compliance of thoracic wall and lung, thereby limiting the dilation of upper airway and lung, attenuating the stiffening effect of tracheal tug on the pharyngeal upper airway segment, and finally causing the airway collapse. Besides, adipose tissues secrete kinds of hormonally active agents and inflammatory cytokines such as leptin, TNF-α, IL-6, etc. On the other hand, OSA can also lead to obesity via a variety of mechanisms: Disturbed sleep architecture and intermittent hypoxia lead to neurohormonal abnormalities, such as changes in the proportion of leptin-ghrelin, subsequently increasing the oral intake; deprival of deep sleep reduces the production of growth hormone which can decompose the adipose tissue; reduction of daytime activities aggravates obesity and increases the difficulty to lose weight; IR, caused by the lower sensitivity of insulin and affinity of its receptors in OSA, plays a significant role in the mechanism of metabolic syndrome like obesity.

Obesity is also a significant risk predictor of asthma. Increasing weight causes more frequent or more severe asthma exacerbations and more difficult-to-control symptoms. Obesity can induce or aggravate the restrictive/obstructive ventilation function disturbance and small airway damage by the effect of fat deposition and inflammation.

**Gastroesophageal reflux disease**

Gastroesophageal reflux disease (GERD) is an independent predictor for habitual snoring. Green et al. and Valipour et al. reported that GERD was comorbidity in 62% and 58% of patients with OSA syndrome, respectively. The upper airway occlusion in OSA causes a higher negative intrathoracic pressure and an increasing transdiaphragmatic pressure. In the meantime, autonomic nervous system dysfunction, frequent arousals, and swallowing cause transient lower esophageal sphincter relaxation, which can finally lead to GERD. On the contrary, the clearance ability of gastric acid in patients with GERD usually decreases at night. The proximal migration of gastric acid causes pharyngeal spasm and mucosal exudative neurogenic inflammation, which makes the airway more prone to collapse during sleep. Besides, laryngitis and edema caused by reflux can further aggravate the obstructive degree.

In addition, studies found patients with GERD more easily suffered asthma attack. GERD is one of the risk factors of asthma attack. The vague is activated in GERD by stimulating the acid-sensitive receptors on esophageal mucosa, causing reflex bronchospasm. After microaspiration, the airway mucosa is injured by gastric contents, which can also induce or worsen asthma.
**Clinical Manifestations**

There are many similar clinical manifestations between OSA and asthma, including airflow obstruction in corresponding segment, obviously sleep quality declining and daytime fatigue. Both diseases often attack during the night or in the early morning. Series of cardiovascular system complications occur if poorly controlled. Therefore, in clinical work, it is difficult to differentiate OSA from nocturnal asthma just based on patient’s complaints. Some functional assessments such as bronchial provocation/dilation test or PSG might help. With the growing awareness of the relationship between the two diseases, some scholars defined them as “alternative overlap syndrome” to help us better stratify the therapies.

**Diagnosis**

At present, most of the diagnostic procedures of OSA rely on PSG.\(^5\) By monitoring overnight brain electrical activity, respiration, thoracic-abdominal motion, finger oxygen saturation, etc., physicians can get information about the distribution of sleeping state, frequency, and duration of apnea and hypoxia. By contrast, the diagnosis of asthma principally relies on symptoms, accompanied by lung function, allergy test, etc. Since OSA is often neglected in clinical work, current asthma guideline has recommended the testing for OSA in those overweight or obese patients with poorly controlled asthma. By inquiring the patient or his/her bed partner, the symptoms of snoring, witnessed apneas, excessive fatigue, or sleepiness during wakefulness, physicians can get a preliminary inspection.\(^5\)

**Therapies**

CPAP has been accepted as the main nonsurgical treatment for OSA, which was introduced by Sullivan in 1981.\(^6\) It was found to improve asthmatic symptoms in patients combined with OSA as well. Chan et al. assessed a 2-week course of CPAP treatment in nine persons and finally found that it could decrease the frequency of asthma attack all day long, reduce bronchodilator use, and improve peak expiratory flow rates pre-/post-bronchodilators. However, the peak expiratory flow rate returned to levels prior to the therapy after the cessation of CPAP.\(^7\) Guilleminault et al. studied 10 people and demonstrated that 6–9 months of CPAP treatment can successfully eliminate nocturnal asthma attacks.\(^8\) Ciftci et al. reported that 2-month CPAP therapy resulted in a significant improvement in asthma nocturnal symptom score, but no change in lung function as forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC, and forced expiratory flow 25–75%. Consequently, CPAP treatment is definitely associated with lower odds of nocturnal asthma during the therapy but presents no improvement in lung function after the cessation of it.\(^9\)

CPAP treatment can improve the asthma symptom through a variety of pathways. It decreases the airway resistance to avoid peripheral airway collapse by increasing airway average pressure, minute ventilation, FVC, and total lung capacity. Carr and Essex provided the anesthetic dogs with 20 cm H₂O CPAP treatment and noticed that the diameter of the major airway had increased by 33–71%.\(^1\) CPAP treatment can also lower the bronchial smooth muscle’s high reactivity to acetylcholine and help the airway dilation. Besides, as it is mentioned above, the local inflammatory effect caused by OSA can be inhibited by the therapy. Also, CPAP can eliminate the hypoxia caused by OSA and lower the levels of leptin and VEGF. In addition, CPAP alleviates GERD by decreasing the thoracic-abdomen pressure gradient and reducing the chance of awakening.

Limitations also do exist. Heater humidifiers are needed to avoid cold and dry air from inducing asthma or sputum scab formation. Humidifiers must be kept clean to prevent microorganism from propagating in the warm and humid environment and going down the airway. Besides, a study done by Martin and Pak showed that CPAP was hard to intolerant for those nonapneic nocturnal asthmatics. Instead, sleep was interrupted for its uncomfortability.\(^1\) That is to say, CPAP treatment is not recommended for those patients.

In summary, OSA and asthma are common conditions. The term of “alternative overlap syndrome” may represent as a condition with important common characteristics of the two diseases. As the dual interaction between them, we should raise our awareness and provide proper therapy timely to relieve the pain of the patients. Traditional CPAP treatment can improve the asthma symptoms in those people. However, there are still some limitations. Further definitive confirmation completed by large randomized controlled trials, as well as an evaluation to analyze the lower airway structure and function in the two conditions, are still necessary.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5.
2. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78.
3. Knuiman M, James A, Divitini M, Bartholomew H. Longitudinal study of risk factors for habitual snoring in a general adult population: The Busselton Health Study. Chest 2006;130:1779-83.
4. Ekici A, Ekici M, Kurtipek E, Keles H, Kara T, Tunekol M, et al. Association of asthma-related symptoms with snoring and apnea and effect on health-related quality of life. Chest 2005;128:3358-63.
5. Auckley D, Mouillet M, Shuman Z, Mustafa M. Findings of a Berlin Questionnaire survey: Comparison between patients seen in an asthma clinic versus internal medicine clinic. Sleep Med 2005;9:494-9.
6. Julien JY, Martin JG, Ernst P, Olivenstein R, Hamid Q, Lemiére C, et al. Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma. J Allergy Clin Immunol 2009;124:371-6.
7. Alharbi M, Almutairi A, Alotaibi D, Alotaibi A, Shaikh S, Bahammam AS. The prevalence of asthma in patients with obstructive sleep apnoea. Prim Care Respir J 2009;18:328-30.
Evidence of neutrophilic low ratio during sleep in patients with respiratory system: D: E: Defining of the persistent adult phenotypes. Associations and treatment implications. Sleep Med Rev 2014;18:165‑71.

Skoczynski S, Ograbek‑Król M, Tazbirek M, Semik‑Orzech A, Kohler M, Ayers L, Pepperell JC, Packwood KL, Ferry B, Karamanli H, Özol D, Ugur KS, Yildirim Z, Armutçu F, Bozkurt B, Prasad B, Nyenhuis SM, Weaver TE. Obstructive sleep apnea and inflammation in persistent asthma. Thorax 1992;47:101‑5.

McNicholas WT. Obstructive sleep apnea and inflammation. Prog Cardiovasc Dis 2009;51:392‑9.

Aihara K, Oga T, Chihara Y, Harada Y, Tanizawa K, Handa T, McNicholas WT. Obstructive sleep apnea and systemic inflammation in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129‑34.

Younes M. Role of arousals in the pathogenesis of obstructive sleep apnea. Am J Respir Crit Care Med 2002;165:670‑6.

Serafino‑Agrusa L, Spatara M, Scichilone N. Asthma and metabolic syndrome: Current knowledge and future perspectives. World J Clin Cases 2015;3:285‑92.

Ballard RD. Sleep, respiratory physiology, and nocturnal asthma. Chronobiol Int 1999;16:565‑80.

Alkhali M, Schulman E, Gettys J. Obstructive sleep apnea syndrome and asthma: What are the links? J Clin Sleep Med 2009;5:71‑8.

McNicholas WT. Obstructive sleep apnea and inflammation. Prog Cardiovasc Dis 2009:51:392‑9.

Aihara K, Oga T, Chihara Y, Harada Y, Tanizawa K, Handa T et al. Analysis of systemic and airway inflammation in obstructive sleep apnea. Sleep Breath 2013;17:597‑604.

Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313‑6.

Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G et al. Elevated levels of C‑reactive protein and interleukin‑6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129‑34.

Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V et al. Elevated C‑reactive protein in patients with obstructive sleep apnea. Circulation 2002;105:2462‑4.

Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor‑kappaB‑dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006;174:824‑30.

Wenzel SE. Asthma: Defining of the persistent adult phenotypes. Lancet 2006;368:804‑13.

Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: Evidence of neutrophilic inflammation and increased sputum interleukin‑8. Chest 2001;119:1326‑9.

Teodorescu M, Broymann O, Curran‑Everett D, Sorokine RL, Crisafi G, Bleecker ER et al. Obstructive sleep apnea risk, asthma burden, and lower airflow inflammation in adults in the Severe Asthma Research Program (SARP) II. J Allergy Clin Immunol Pract 2015;3:566‑75.e1.

Prasad B, Nyenhuis SM, Weaver TE. Obstructive sleep apnea and asthma: Associations and treatment implications. Sleep Med Rev 2001;5:181‑91.

Karamanli H, Özol D, Ugar KS, Yurtlu S, Alparslan S, Saygi A et al. Influence of CPAP treatment on airway and systemic inflammation in OSAS patients. Sleep Breath 2012;16:1151‑8.

Kohler M, Ayers L, Peppercull JC, Packwood KL, Ferry B, Crosthwaite N et al. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: A randomised controlled trial. Thorax 2009;64:67‑73.

Skoczynski S, Ogroblicki‑Kol M, Faizirek M, Semik‑Orzech A, Pierzchala W. Short‑term CPAP treatment induces a mild increase in inflammatory cells in patients with sleep apnea syndrome. Rhinology 2008;46:144‑50.

Sideleva O, Suratt BT, Black KE, Tharp WG, Pratley RE, Forgione P et al. Obesity and asthma: An inflammatory disease of adipose tissue not the airway. Am J Respir Crit Care Med 2012;186:598‑605.

Shore SA, Schwartzman IN, Mellema MS, Flynt L, Imrich A, Johnston RA. Effect of leptin on allergic airway responses in mice. J Allergy Clin Immunol 2005;115:103‑9.

Imagawa S, Yamaguchi Y, Imai S, Hasegawa Y, Mukai HY et al. Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea – Hypopnea syndrome. Blood 2001;98:1255‑7.

Simcock DE, Kanabar V, Clarke GW, O’Connor BJ, Lee TH, Hirst SJ. Proangiogenic activity in bronchial lavage fluid from patients with asthma. Am J Respir Crit Care Med 2007;176:146‑53.

Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long‑term cardiovascular outcomes in men with obstructive sleep apnoea‑hypopnoea with or without treatment with continuous positive airway pressure: An observational study. Lancet 2005;365:1046‑53.

Fung JW, Li TS, Choy DK, Yip GW, Ko FW, Sanderson JE et al. Severe obstructive sleep apnea is associated with left ventricular diastolic dysfunction. Chest 2002;121:422‑9.

Fletcher EC, Bao G, Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 1999;34:309‑14.

Snashall PD, Chung KF. Airway obstruction and bronchial hyperresponsiveness in left ventricular failure and mitral stenosis. Am Rev Respir Dis 1991;144:945‑56.

Tanniser R, Pepin JL, Wuydam B, Deschaux C, Levy P. Expiratory changes in pressure: Flow ratio during sleep in patients with sleep‑disordered breathing. Sleep 2004;27:240‑8.

Yglesia M, Tol N, Solomonov A, Rubin AH, Darvel D. Difficult‑to‑control asthma and obstructive sleep apnea. J Asthma 2003;40:865‑71.

Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep‑disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J Allergy Clin Immunol 1997;99:575‑62.

Scharf MB, Cohen AP. Diagnostic and treatment implications of nasal obstruction in snoring and obstructive sleep apnea. Ann Allergy Asthma Immunol 1998;81:279‑87.

Kalpakioiu AF, Kavut AB, Ekici M. Allergic and nonallergic rhinitis: The threat for obstructive sleep apnea. Ann Allergy Asthma Immunol 2009;103:20‑5.

Togias A. Rhinitis and asthma: Evidence for respiratory system integration. J Allergy Clin Immunol 2003;111:171‑83.

Gaki E, Papastheodorou G, Ishaki E, Grammenou V, Papa I, Loukides S. Leukotriene E(4) in urine in patients with asthma and COPD – The effect of smoking habit. Respir Med 2007;101:826‑32.

Schwartz AR, Patil SP, Laffan AM, Polotsky V, Schneider H, Smith PL. Obesity and obstructive sleep apnea: Pathogenic mechanisms and therapeutic approaches. Pro Am Thorac Soc 2008;5:185‑92.

Soylu AC, Levent E, Sariman N, Yurtlu S, Alparslan S, Saygi A. Obstructive sleep apnea syndrome and anthropometric obesity indexes. Sleep Breath 2012;16:1151‑8.

Davies RJ, Ali NJ, Stradling JR. Neck circumference and other clinical features in the diagnosis of the obstructive sleep apnoea syndrome. Thorax 1992;47:101‑5.

Canapari CA, Hoppin AG, Kinane TB, Thomas BJ, Torriani M, Katz ES. Relationship between sleep apnea, fat distribution, and insulin resistance in obese children. J Clin Sleep Med 2011;7:268‑73.

Redline S, Storfer‑Isser A, Rosen CL, Johnson NL, Kirchner HL, Johnston RA. Effect of leptin on allergic airway responses in mice. J Allergy Clin Immunol 2005;115:103‑9.

Imagawa S, Yamaguchi Y, Imai S, Hasegawa Y, Mukai HY et al. Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea – Hypopnea syndrome. Blood 2001;98:1255‑7.

Simcock DE, Kanabar V, Clarke GW, O’Connor BJ, Lee TH, Hirst SJ. Proangiogenic activity in bronchial lavage fluid from patients with asthma. Am J Respir Crit Care Med 2007;176:146‑53.

Berg S, Hybbinette JC, Gislason T, Ovessen J. Intrathoracic pressure variations in obese habitual snorers. J Otolaryngol 1995;24:238‑41.
55. Ing AI, Ngu MC, Breslin AB. Obstructive sleep apnea and gastroesophageal reflux. Am J Med 2000;108 Suppl 4a:120S-5S.
56. Emilsson ÖI, Bengtsson A, Franklin KA, Torén K, Benedíktsdóttir B, Farkhooy A, et al. Nocturnal gastro-oesophageal reflux, asthma and symptoms of OSA: A longitudinal, general population study. Eur Respir J 2013;41:1347-54.
57. Ishizuka T, Hisada T, Kamide Y, Aoki H, Seki K, Honjo C, et al. The effects of concomitant GERD, dyspepsia, and rhinosinusitis on asthma symptoms and FeNO in asthmatic patients taking controller medications. J Asthma Allergy 2014;7:131-9.
58. Kushida CA, Littner MR, Morgenthaler T, Alessi CA, Bailey D, Coleman J Jr, et al. Practice parameters for the indications for polysomnography and related procedures: An update for 2005. Sleep 2005;28:499-521.
59. Teodorescu M, Consens FB, Bria WF, Coffey MJ, McMorris MS, Weatherwax KJ, et al. Correlates of daytime sleepiness in patients with asthma. Sleep Med 2006;7:607-13.
60. Sullivan CE, Issa FG, Berthon-Jones M, Eves L. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1981;1:862-5.
61. Chan CS, Woolcock AJ, Sullivan CE. Nocturnal asthma: Role of snoring and obstructive sleep apnea. Am Rev Respir Dis 1988;137:1502-4.
62. Guilleminault C, Quera-Salva MA, Powell N, Riley R, Romaker A, Partinen M, et al. Nocturnal asthma: Snoring, small pharynx and nasal CPAP. Eur Respir J 1988;1:902-7.
63. Ciftci TU, Ciftci B, Guven SF, Kocaturk O, Turktas H. Effect of nasal continuous positive airway pressure in uncontrolled nocturnal asthmatic patients with obstructive sleep apnea syndrome. Respir Med 2005;99:529-34.
64. Carr DT, Essex HE. Certain effects of positive pressure respiration on the circulatory and respiratory systems. Am Heart J 1946;31:53-73.
65. Martin RJ, Pak J. Nasal CPAP in nonapneic nocturnal asthma. Chest 1991;100:1024-7.